Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study

Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials

“…Several other RCTs on this topic are currently being undertaken (DAPT trial 40 , ISAR-SAFE 41 , OPTIDUAL 42 , Nobori DAPT (NCT01514227), EDUCATE (NCT01069003), DAPT-STEMI (NCT01459627), SMART-DATE (NCT1701453)). All of these trials are comparing between 6 to 12 months of DAPT against 12 to 30 months and looking at different clinical presentations and stent platforms.…”

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

“…Currently, large-scale, randomized, clinical trials are being performed to address questions about the appropriate duration of dual antiplatelet therapy in patients who have received drug-eluting stents. 12,13 We have previously reported that, compared with aspirin alone, continuation of dual antiplatelet therapy for >12 months after drug-eluting stent implantation is not beneficial. 14 Furthermore, the long-term dual-therapy arm was associated with a trend toward increased risk of cardiac death, myocardial infarction, and stroke.…”

Recent advances in antithrombotic therapy after acute coronary syndrome

“…[42][43][44][45][46] Several trials are underway testing shorter and longer durations of dual antiplatelet therapy. [47][48][49] Attempts to personalize therapy with the use of platelet function testing or genetic testing to adjust clopidogrel dose have been unsuccessful. 50,51 Even after controlling for known factors that affect drug metabolism and compliance, variability in clopidogrel response is still large.…”